AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT01451294
Drug: Administration of phenylephrine
RxNorm normalized name: OIL OF CAMPHOR
DrugBank: Phenylephrine (DB00388)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Phenylephrine: 50-100µg
Trial: NCT01451294
Drug: Administration of ephedrine
RxNorm normalized name: Ephedrine
DrugBank: Ephedrine (DB01364)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ephedrine: 5- 10 mg
Trial: NCT03156231
Drug: ACETAZOLAMIDE oral capsule
RxNorm normalized name: Acetazolamide
DrugBank: Acetazolamide (DB00819)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administration of 125mg acetazolamide in the morning, 250mg in the evening, starting 24 hours before departure to 3200m
Trial: NCT01713777
Drug: Lamotrigine Generic A
RxNorm normalized name: Lamotrigine
DrugBank: Lamotrigine (DB00555)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01713777
Drug: Lamotrigine generic B
RxNorm normalized name: Lamotrigine
DrugBank: Lamotrigine (DB00555)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01692197
Drug: E7070
RxNorm normalized name: Capivasertib
DrugBank: Capivasertib (DB12218)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg/m2 intravenously over 1 hour on Day 1 and Day 8 every 3 weeks.
Trial: NCT01692197
Drug: Idarubicin
RxNorm normalized name: Idarubicin
DrugBank: Idarubicin (DB01177)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 8 mg/m2 by vein over 1 hour daily for 3 days (Days 9-11).
Trial: NCT01692197
Drug: Cytarabine
RxNorm normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1.0 g/m2 by vein daily on Days 9 - 12 (age \<60 years) or Days 9 - 11 (age \> 60 years).
Trial: NCT01692197
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 10 mg by vein daily for 3 - 4 days with cytarabine.
Trial: NCT02120924
Drug: Azelaic acid
RxNorm normalized name: Azelaic Acid
DrugBank: Azelaic acid (DB00548)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dosage form: Topical gel Dosage: Apply gel to the affected areas of the face twice daily for 12 weeks. The amount needed depends upon the size of the lesion site. Assure that enough is applied to adequately cover each lesion. Normally 0.5 g of gel is used on each 5 cm x 5 cm lesion site.
Trial: NCT02120924
Drug: Finacea
RxNorm normalized name: Finacea
DrugBank: Azelaic acid (DB00548)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dosage form: Topical gel Dosage: Apply gel to the affected areas of the face twice daily for 12 weeks. The amount needed depends upon the size of the lesion site. Assure that enough is applied to adequately cover each lesion. Normally 0.5 g of gel is used on each 5 cm x 5 cm lesion site.
Trial: NCT00969852
Drug: Sertraline
RxNorm normalized name: Sertraline
DrugBank: Sertraline (DB01104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Multiple doses of 5, 25, and 50 mg Sertraline for 6 days each period.
Trial: NCT01295606
Drug: Cefazolin
RxNorm normalized name: Cefazolin
DrugBank: Cefazolin (DB01327)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: iv cefazolin (50mg/kg, 3 times a day) will be given as a routine prophylaxis treatment
Trial: NCT04391582
Drug: silver sulfadiazine cream 1%
DrugBank: Sulfadiazine (DB00359)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: After cleaning the lesion with tap water and 2% chlorhexidine gluconate, a thin layer of silver sulfadiazine cream 1% was applied and covered with gauze and bandage. In these patients, the dressings were changed daily
Trial: NCT03208972
Drug: low dose hCG
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT03208972
Drug: Corifollitropin Alfa
RxNorm normalized name: corifollitropin alfa
DrugBank: Corifollitropin alfa (DB09066)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: Corifollitropin Alfa (Elonva) dosage depending on weight, once administered first day of ovarian stimulation for all subjects, and on day 7 they proceed with the treatment of the allocated group.~\<60 kg: Elonva 100 MCG \> 60 kg: Elonva 150 MCG
Trial: NCT01016834
Drug: Sumatriptan
RxNorm normalized name: Sumatriptan
DrugBank: Sumatriptan (DB00669)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: subcutaneous injection, 6 mg, per migraine attack, no more than two administrations within a 24 hr period
Trial: NCT02192450
Drug: Insulin aspart/glargine
DrugBank: Insulin aspart (DB01306)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT02192450
Drug: Insulin aspart/degludec
DrugBank: Insulin aspart (DB01306)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT00260923
Drug: aliskiren
RxNorm normalized name: Aliskiren
DrugBank: Aliskiren (DB09026)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00612066
Drug: rosiglitazone maleate
RxNorm normalized name: Rosiglitazone Maleate
DrugBank: Rosiglitazone (DB00412)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04260191
Drug: AMG 910
RxNorm normalized name: AMG 108
DrugBank: AMG 108 (DB05545)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV Infusion
Trial: NCT01690403
Drug: rifapentine (M000473)
RxNorm normalized name: Rifapentine
DrugBank: Rifapentine (DB01201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form:tablet~Route of administration: oral
Trial: NCT02843789
Drug: Tocilizumab
RxNorm normalized name: Tocilizumab
DrugBank: Tocilizumab (DB06273)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT01513317
Drug: Siltuximab
RxNorm normalized name: Siltuximab
DrugBank: Siltuximab (DB09036)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 15 mg/kg administered as a 1-hour intravenous infusion every 4 weeks
Trial: NCT01891643
Drug: Lenalidomide
RxNorm normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT01825551
Drug: Granulocyte Colony Stimulating Factor
RxNorm normalized name: Granulocyte colony stimulating factor
DrugBank: Filgrastim (DB00099)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT01027910
Drug: PCI-24781
RxNorm normalized name: PCI-27483
DrugBank: PCI-27483 (DB13000)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsules taken orally for 5 consecutive days starting on Day 1 of each 3 week cycle
Trial: NCT01027910
Drug: GCSF
RxNorm normalized name: GlycoPEG-GCSF
DrugBank: GlycoPEG-GCSF (DB06022)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered on Day 5 of each 3 weeks cycle in Arm 1 if determined to be clinically indicated, and in all patients enrolled into Arm 2
Trial: NCT02805842
Drug: Tacrolimus BID
RxNorm normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administration of Tacrolimus BID
Trial: NCT01891643
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT03063229
Drug: Doubly Labelled Water
DrugBank: Water (DB09145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The Doubly Labelled water will be prescribed for the participants and they will drink their 100ml dose of the stable isotope. Dose depends on the eight of the participant. The participant will then collect urine samples at home on day 5, 10 and 14 after drinking the water. They will store them in the freezer until they can bring them back to us.
Trial: NCT02717949
Drug: sofosbuvir/ledipasvir
DrugBank: Sofosbuvir (DB08934)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: sofosbuvir ledipasvir fixed dose combination given once a day by mouth
Trial: NCT02717949
Drug: sofosbuvir
RxNorm normalized name: Sofosbuvir
DrugBank: Sofosbuvir (DB08934)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: sofosbuvir 400 mg given one a daily orally and weight-based ribavirin given twice a day orally
Trial: NCT02717949
Drug: Ribavirin
RxNorm normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: ribavirin 1200 mg given orally in divided dose for those \>75kg and 1000 mg in divided dose for those \<75 kg.
Trial: NCT03529526
Drug: KN046
RxNorm normalized name: Crizotinib
DrugBank: Crizotinib (DB08865)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: The modified phase I 3 + 3 study design was used in dose escalation from low dose to high dose to determine the MTD.Sequential assignment of Patient cohorts to one of five dose levels of KN046: 0.3 mg/kg,1 mg/kg,3 mg/kg,5 mg/kg,10 mg/kg.
Trial: NCT01657201
Drug: Voriconazole 200mg
RxNorm normalized name: VORICONAZOLE 200MG TAB
DrugBank: Voriconazole (DB00582)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Voriconazole 200mg, Intravenous administration
Trial: NCT00023673
Drug: carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00023673
Drug: paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT03843502
Drug: Kava Dietary Supplement
RxNorm normalized name: KAVA
DrugBank: Kava (DB01322)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will be given three 75mg kava capsules.
Trial: NCT02497326
Drug: Polyfax & Lignocain gel or silvazine cream
DrugBank: Poly(lactic acid) (DB15037)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: olyfax skin ointment plus Lignocain gel will be applied on superficial PTB area and silver sulphadiazine cream on deep PTB in morning and evening after wound wash.
Trial: NCT02497326
Drug: Tramadol
RxNorm normalized name: Tramadol
DrugBank: Tramadol (DB00193)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: IV Analgesic ( Inj. Tramadol 10mg/dose) will only be given to the patients (in both groups) having pain score \>4, assessed 3 times a day by Numeric Visual Analogue scale (NVAS).
Trial: NCT01019655
Drug: Nadroparin calcium
RxNorm normalized name: nadroparin calcium
DrugBank: Nadroparin (DB08813)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: nadroparin calcium (fraxiparin®) 0.3 mL daily during pregnancy and six weeks post partum
Trial: NCT01040871
Drug: VELCADE
RxNorm normalized name: Velcade
DrugBank: Bortezomib (DB00188)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: VELCADE intravenous on Days 1, 4, 8, and 11 of a 21 day (3 week) cycle for 6 cycles.
Trial: NCT01040871
Drug: Rituximab
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Rituximab intravenous on Day 1 of a 21 day (3 week) cycle for 6 cycles
Trial: NCT01040871
Drug: Prednisone
RxNorm normalized name: Prednisone
DrugBank: Prednisone (DB00635)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Orally on Day 1 to Day 5 of a 21 day (3 week) cycle for 6 cycles
Trial: NCT01040871
Drug: Vincristine
RxNorm normalized name: Vincristine
DrugBank: Vincristine (DB00541)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous on Day 1 of a 21 day (3 week) cycle for 6 cycles
Trial: NCT01256775
Drug: NCX-4016
RxNorm normalized name: NCX-1000
DrugBank: NCX-1000 (DB16026)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NCX4016 800 mg b.i.d. for 6 months on top of aspirin 100 mg o.d.
Trial: NCT00064441
Drug: OPC-6535 Tablets (drug)
RxNorm normalized name: OPC-14523
DrugBank: OPC-14523 (DB05422)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01465802
Drug: Dacomitinib
RxNorm normalized name: DACOMITINIB
DrugBank: Dacomitinib (DB11963)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Dacomitinib 45 mg orally daily on a continuous schedule until disease progression, toxicity, death or withdrawal of consent
Trial: NCT01465802
Drug: Dacomitinib
RxNorm normalized name: DACOMITINIB
DrugBank: Dacomitinib (DB11963)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Dacomitinib 45 mg orally daily on a continuous schedule for the first 10 days in Cycle 1, followed by 4 days off treatment, followed by continuous daily dosing until disease progression, toxicity, death or withdrawal of consent
Trial: NCT01465802
Drug: Probiotic
RxNorm normalized name: PROBIOTIC
DrugBank: Lactobacillus acidophilus (DB15823)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VSL#3 probiotic 4 capsules orally daily or 1 sachet orally daily for up to 5 weeks (starting between Day minus 7 to Day minus 4 and continuing through Day 28)
Trial: NCT01465802
Drug: Alclometasone cream
RxNorm normalized name: alclometasone Topical Cream
DrugBank: Alclometasone (DB00240)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical alclometasone diproprionate cream 0.05% applied to face, hands, feet, neck, back and chest at bedtime for 4 weeks
Trial: NCT00229684
Drug: Tesaglitazar
RxNorm normalized name: Tesaglitazar
DrugBank: Tesaglitazar (DB06536)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg once daily in oral form
Trial: NCT00229684
Drug: pioglitazone
RxNorm normalized name: Pioglitazone
DrugBank: Pioglitazone (DB01132)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 45 mg once daily in oral form
Trial: NCT02252081
Drug: metformin
RxNorm normalized name: Metformin
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 500 to 1500 mg orally per day for 16 weeks if eGFR \> 45 ml/min; 500 to 1000 mg orally per day for 16 weeks if eGFR =\< 45 ml/min
Trial: NCT01297842
Drug: Ertapenem
RxNorm normalized name: Ertapenem
DrugBank: Ertapenem (DB00303)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Ertapenem 1 gram per day for 7 to 14 days
Trial: NCT01297842
Drug: Meropenem or Imipenem
RxNorm normalized name: Imipenem
DrugBank: Meropenem (DB00760)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Meropenem or Imipenem 0.5 to 1 gram 3 to 4 times per day for 7 to 14 days
Trial: NCT02247310
Drug: Interferon beta-1b (Betaferon®, BAY 86-5046)
RxNorm normalized name: Interferon Beta-1B
DrugBank: Interferon beta-1b (DB00068)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients will be treated with Betaferon
Trial: NCT02595684
Drug: Tadalafil
RxNorm normalized name: Tadalafil
DrugBank: Tadalafil (DB00820)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tadalafil capsules: 5 mg, one per day, at night, during 28 days.
Trial: NCT00965900
Drug: Propranolol
RxNorm normalized name: Propranolol
DrugBank: Propranolol (DB00571)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: * start with 20 mg of propranolol b.i.d~* Adjust by 20-40 mg/day reaching reduction by 25 percent in HR or HR less than 55/min~* After reaching target HR, then FU according to a preset schedule (at 1, 2, 3 months after initial treatment, then every 3 months until 36 months)
Trial: NCT00476424
Drug: efavirenz
RxNorm normalized name: Efavirenz
DrugBank: Efavirenz (DB00625)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: EFV 400 mg OD for 14 days EFV 600 mg OD for 14 days
Trial: NCT02639377
Drug: Chlorhexidine gluconate
RxNorm normalized name: Chlorhexidine Gluconate
DrugBank: Chlorhexidine (DB00878)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01136551
Drug: Huperzine A
RxNorm normalized name: Huperzine A
DrugBank: Huperzine A (DB04864)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each volunteer will receive single dose of three different formulations of Huperzine A. One immediate release formulation of 0.4mg and two different controlled release formulations at same dose. Between the study phases will be a washout period of at least 21 days.
Trial: NCT00961532
Drug: DDAVP injection (desmopressin acetate)
RxNorm normalized name: desmopressin acetate Injection [DDAVP]
DrugBank: Desmopressin (DB00035)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 0.4 mcg/kg in 250 mL NS intravenously once over 30 minutes
Trial: NCT01645475
Drug: Desmopressin lyophilisate (Melt)
DrugBank: Desmopressin (DB00035)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Patient receives Desmopressin lyophilisate (Melt).
Trial: NCT00028834
Drug: gemcitabine hydrochloride
RxNorm normalized name: Gemcitabine Hydrochloride
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT01211912
Drug: Arm 1 (20 patients)
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Acetaminophen 1000 mg by mouth once
Trial: NCT01211912
Drug: Arm 2 (34 patients)
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Acetaminophen 1000 mg by mouth once
Trial: NCT02773979
Drug: Chloroquine
RxNorm normalized name: Chloroquine
DrugBank: Chloroquine (DB00608)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administered as 600mg PO, day 1, 300mg PO days 8, 15, 22.
Trial: NCT00664144
Drug: Rasburicase (SR29142)
RxNorm normalized name: Rasburicase
DrugBank: Rasburicase (DB00049)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT04425226
Drug: Pembrolizumab Injection [Keytruda]
RxNorm normalized name: pembrolizumab Injection [Keytruda]
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Pembrolizumab (Keytruda, MSD China) is a recombinant anti-human PD-1 monoclonal antibody.
Trial: NCT04425226
Drug: Lenvatinib Oral Product
RxNorm normalized name: lenvatinib Oral Product
DrugBank: Lenvatinib (DB09078)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Lenvatinib (Lenvima, Eisai China) is a novel angiogenesis inhibitor which targets vascular endothelial growth factor 1-3, fibroblast growth factor receptor 1-4, platelet-derived growth factor receptor β, RET and KIT
Trial: NCT00652457
Drug: Memantine
RxNorm normalized name: Memantine
DrugBank: Memantine (DB01043)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 10 mg BID x 3 months
Trial: NCT01046110
Drug: insulin degludec
RxNorm normalized name: Insulin Degludec
DrugBank: Insulin degludec (DB09564)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Injected under the skin once daily for 26 weeks. The doses will be individually adjusted.
Trial: NCT01046110
Drug: sitagliptin
RxNorm normalized name: Sitagliptin
DrugBank: Sitagliptin (DB01261)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Sitagliptin tablets administered orally once a day at the same time every day for 26 weeks
Trial: NCT00968110
Drug: omalizumab
RxNorm normalized name: Omalizumab
DrugBank: Omalizumab (DB00043)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Dosing table established for omalizumab
Trial: NCT04116554
Drug: 0.25% bupivacaine.
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 20 mL of 0.25% bupivacaine and the same procedure will be repeated on the other side
Trial: NCT00304070
Drug: Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT00304070
Drug: Etoposide
RxNorm normalized name: Etoposide
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT00304070
Drug: Mitotane
RxNorm normalized name: Mitotane
DrugBank: Mitotane (DB00648)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given orally
Trial: NCT02772068
Drug: Istaroxime
RxNorm normalized name: Istaroxime
DrugBank: Istaroxime (DB06157)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will be given Istaroxime, a novel SERCA2a activator one hour prior and during exercise.
Trial: NCT01223079
Drug: r-hFSH
RxNorm normalized name: Prolease-r-hFSH
DrugBank: Prolease-r-hFSH (DB05826)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: r-hFSH dose to be determined by the patient's primary doctor and adjusted according to their response
Trial: NCT00377676
Drug: Cycloset
RxNorm normalized name: Cycloset
DrugBank: Bromocriptine (DB01200)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Usual diabetes therapy plus Cycloset
Trial: NCT03206021
Drug: 5 Azacytidine
RxNorm normalized name: 5 azacytidine
DrugBank: Cytidine (DB02097)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose escalation of carboplatin combined with 5'azacytidine
Trial: NCT00390390
Drug: Lansoprazole
RxNorm normalized name: Lansoprazole
DrugBank: Lansoprazole (DB00448)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01405157
Drug: methylprednisolone
RxNorm normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: constituted powder for oral suspension 4 mg/mL single dose at 16 mg
Trial: NCT01405157
Drug: methylprednisolone
RxNorm normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: tablets 16 mg single dose
Trial: NCT00902200
Drug: AR-12286
RxNorm normalized name: AR-9281
DrugBank: AR-9281 (DB06345)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: See arms
Trial: NCT00902200
Drug: AR-12286 vehicle
RxNorm normalized name: AR-9281
DrugBank: AR-9281 (DB06345)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: See arms
Trial: NCT03586999
Drug: Nivolumab
RxNorm normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Nivolumab injection is to be administered as an IV infusion.
Trial: NCT03586999
Drug: Etoposide
RxNorm normalized name: Etoposide
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dosage calculations will be based on the patient's body surface area (BSA) at baseline, recommend using the Mosteller formula and administered through IV. Dose adjustments at the beginning of each cycle do not need to be made unless there has been a \>10% weight gain or loss. Patients receive six 21-day cycles of the medications.
Trial: NCT03586999
Drug: Oncovin
RxNorm normalized name: Oncovin
DrugBank: Vincristine (DB00541)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dosage calculations will be based on the patient's body surface area (BSA) at baseline, recommend using the Mosteller formula and administered through IV. Dose adjustments at the beginning of each cycle do not need to be made unless there has been a \>10% weight gain or loss. Patients receive six 21-day cycles of the medications.
Trial: NCT03586999
Drug: Hydroxydaunorubicin
RxNorm normalized name: Hydroxydaunorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dosage calculations will be based on the patient's body surface area (BSA) at baseline, recommend using the Mosteller formula and administered through IV. Dose adjustments at the beginning of each cycle do not need to be made unless there has been a \>10% weight gain or loss. Patients receive six 21-day cycles of the medications.
Trial: NCT00922610
Drug: methoxy polyethylene glycol-epoetin beta [Mircera]
DrugBank: Methoxy polyethylene glycol-epoetin beta (DB09107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: sc every 2 weeks at a starting dose of 0.6micrograms/kg;subsequently every 4 weeks